DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 156 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $636,540 | -10.5% | 41,200 | -5.1% | 0.00% | 0.0% |
| Q4 2022 | $711,326 | -17.1% | 43,400 | -10.9% | 0.00% | 0.0% |
| Q3 2022 | $858,000 | +540.3% | 48,700 | +377.5% | 0.00% | – |
| Q2 2022 | $134,000 | -73.2% | 10,200 | -30.6% | 0.00% | -100.0% |
| Q3 2021 | $500,000 | +11.6% | 14,707 | 0.0% | 0.00% | – |
| Q2 2021 | $448,000 | -60.0% | 14,707 | -41.1% | 0.00% | -100.0% |
| Q1 2021 | $1,120,000 | -10.5% | 24,982 | +14.0% | 0.00% | -50.0% |
| Q4 2020 | $1,251,000 | +11.3% | 21,919 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,124,000 | -41.8% | 21,919 | -32.2% | 0.00% | -33.3% |
| Q2 2020 | $1,930,000 | +57.7% | 32,319 | +8.7% | 0.00% | +50.0% |
| Q1 2020 | $1,224,000 | -38.6% | 29,719 | -7.2% | 0.00% | -33.3% |
| Q4 2019 | $1,993,000 | +443.1% | 32,019 | +196.0% | 0.00% | +200.0% |
| Q3 2019 | $367,000 | – | 10,819 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
| SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
| Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
| Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
| Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
| Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
| Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
| SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
| Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
| Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |